128 related articles for article (PubMed ID: 34979297)
1. Optimization of the tumour response threshold in advanced gastroenteropancreatic neuroendocrine carcinomas treated with cisplatin/etoposide combined chemotherapy.
Wang Y; Chen J; Song C; Shi S; Li Z; Feng ST; Luo Y
Eur J Radiol; 2022 Feb; 147():110119. PubMed ID: 34979297
[TBL] [Abstract][Full Text] [Related]
2. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?
Luo Y; Chen J; Shen B; Wang M; Cai H; Xu L; Chen L; Chen M; Li ZP; Feng ST
Eur Radiol; 2018 Dec; 28(12):5250-5257. PubMed ID: 29876704
[TBL] [Abstract][Full Text] [Related]
3. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.
Zhang P; Li J; Li J; Zhang X; Zhou J; Wang X; Peng Z; Shen L; Lu M
Cancer; 2020 May; 126 Suppl 9(Suppl 9):2086-2092. PubMed ID: 32293725
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
[TBL] [Abstract][Full Text] [Related]
5. FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Hadoux J; Afchain P; Walter T; Tougeron D; Hautefeuille V; Monterymard C; Lorgis V; Thuillier F; Baudin E; Scoazec JY; Lepage C; Desgrippes R
Dig Liver Dis; 2021 Jul; 53(7):824-829. PubMed ID: 33994125
[TBL] [Abstract][Full Text] [Related]
6. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Walter T; Malka D; Hentic O; Lombard-Bohas C; Le Malicot K; Smith D; Ferru A; Assenat E; Cadiot G; Lievre A; Kurtz JE; Dahan L; Dubreuil O; Hautefeuille V; Lepere C; Gangloff A; Elhajbi F; Coriat R; Roquin G; Bouarioua N; Granger V; Scoazec JY; Lepage C
Dig Liver Dis; 2018 Feb; 50(2):195-198. PubMed ID: 29258812
[TBL] [Abstract][Full Text] [Related]
7. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
[TBL] [Abstract][Full Text] [Related]
8. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
Ali AS; Grönberg M; Langer SW; Ladekarl M; Hjortland GO; Vestermark LW; Österlund P; Welin S; Grønbæk H; Knigge U; Sorbye H; Janson ET
Med Oncol; 2018 Mar; 35(4):47. PubMed ID: 29511910
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
Fazio N; Spada F; Giovannini M
Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
[TBL] [Abstract][Full Text] [Related]
11. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.
Lu ZH; Li J; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li Y; Shen L
Med Oncol; 2013; 30(3):664. PubMed ID: 23864251
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
18. First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases.
Patta A; Fakih M
Anticancer Res; 2011 Mar; 31(3):975-8. PubMed ID: 21498724
[TBL] [Abstract][Full Text] [Related]
19. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
[TBL] [Abstract][Full Text] [Related]
20. Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
Hadoux J; Walter T; Kanaan C; Hescot S; Hautefeuille V; Perrier M; Tauveron I; Laboureau S; Do Cao C; Petorin C; Blanchet O; Faron M; Leteurtre E; Rousselet MC; Joubert Zakeyh J; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Lombard-Bohas C; Ducreux M; Scoazec JY; Baudin E; ;
Endocr Relat Cancer; 2022 Oct; 29(10):569-580. PubMed ID: 35920609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
